Skip to content
Selank Compound
Where did the Selank facts come from?

Selank references list every paper used here.

Each source has the same number used on other pages. You can open the paper's record and check the claim yourself.

Return to study findingsReview effects and risks

Each number matches one Selank paper

Each number on the site matches a paper below. Russian groups wrote most of the Selank papers. Many full papers are only in Russian. That can make close checking hard.

A DOI is a lasting lookup number for a paper. PubMed is a public list of medical papers and short summaries. Its page isn't always the full paper. You can use either link to check the source behind a claim.

  1. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. ↗
  2. Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. ↗
  3. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. ↗
  4. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. ↗
  5. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. ↗
  6. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. ↗
  7. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. ↗
  8. Kolik LG, Nadorova AV, Kozlovskaya MM, et al. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bull Exp Biol Med. 2014;157(1):52-55. ↗
  9. Kolik LG, Nadorova AV, Seredenin SB, et al. Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice. Bull Exp Biol Med. 2016;162(1):56-59. ↗
  10. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment in Rats. Bull Exp Biol Med. 2019;167(5):641-644. ↗
  11. Konstantinopolsky MA, Chernyakova IV, Kolik LG, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal Syndrome. Bull Exp Biol Med. 2022;173(6):730-733. ↗
  12. Mukhina AY, Mishina ES, Bobyntsev II, et al. Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Selank Administration. Bull Exp Biol Med. 2020;169(2):281-285. ↗
  13. Sarkisova KIu, Kozlovskii II, Kozlovskaia MM, et al. Effects of heptapeptide selank on genetically-based and situation-provoked anxiety in rats. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008;58(2):226-237. ↗
  14. Kolomin TA, Agapova TIu, Agniullin IaV, et al. Transcriptome alteration in the hippocampus under the treatment with the tuftsin analog Selank. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013;63(3):365-374. ↗
  15. Vasil'eva EV, Kondrakhin EA, Salimov RM, et al. Comparison of Pharmacological Effects of Heptapeptide Selank After Intranasal and Intraperitoneal Administration. Eksp Klin Farmakol. 2016;79(9):3-11. ↗
  16. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. ↗
  17. Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Immobilization Stress. Bull Exp Biol Med. 2017;163(4):415-418. ↗
  18. Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/c and C57Bl/6 mice. Eksp Klin Farmakol. 2008;71(5):8-12. ↗
  19. Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, et al. The Influence of Selank on the Level of Cytokines Under the Conditions of Stressogenic Effect. Curr Rev Clin Exp Pharmacol. 2021;16(2):162-167. ↗
  20. Ershov FI, Uchakin PN, Uchakina ON, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. ↗